HIMS Class Action Lawsuit: Investor Deadline Approaches as KTMC Highlights Fraud Claims

A securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS), with investors facing a November 2, 2026, deadline to seek lead plaintiff status. The law firm Kessler Topaz Meltzer & Check, LLP (KTMC) has issued notices to investors regarding the pending litigation, which stems from alleged material misstatements and omissions concerning the company's business practices.

Overview of the Litigation

The lawsuit, captioned *Velanki v. Hims & Hers Health, Inc.*, No. 3:26-cv-09313, was filed in the United States District Court for the Northern District of California. It covers individuals and entities that purchased or acquired HIMS securities between August 4, 2025, and July 29, 2026.

According to the complaint allegations, defendants allegedly failed to disclose key information to investors, including:

• The sharing of consumers' health information with third-party advertising platforms.
• Charging consumers for prescriptions almost immediately after submitting intake forms, despite representations about medical consultations finding appropriate treatments.
• Regulatory scrutiny and potential fees and penalties resulting from the aforementioned practices.

Background on Regulatory Action

The litigation follows a July 29, 2026, action by the Federal Trade Commission (FTC), which filed a complaint accusing HIMS of deceptive and unlawful privacy practices. The FTC complaint alleged that the company shared sensitive health details with advertisers such as Meta Platforms (Facebook) and Snap. Following this disclosure, HIMS's stock price declined by $4.32 per share, or 14.73%, closing at $25.00 per share on July 29, 2026.

Investor Options and Deadlines

Investors who suffered financial losses on HIMS securities during the class period have until November 2, 2026, to apply for lead plaintiff status. Affected parties may choose to:

• Seek appointment as a lead plaintiff through KTMC or other counsel.
• Retain independent counsel of their choice.
• Take no action and remain absent class members.

Serving as a lead plaintiff involves representing the class in directing the litigation, though it does not affect an investor's ability to share in any potential recovery. KTMC notes that representation is handled on a contingency fee basis, and interested investors can contact attorney Jonathan Naji or visit the firm's website for further details and verification of the original announcements.